Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
106 hedge funds and large institutions have $294M invested in Provention Bio, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 12 closing their positions.
358% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 12
208% more call options, than puts
Call options by funds: $10M | Put options by funds: $3.26M
206% more capital invested
Capital invested by funds: $96.2M → $294M (+$198M)
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
68% more funds holding
Funds holding: 63 → 106 (+43)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$27.8M |
| 2 |
PA
Perceptive Advisors
New York
|
+$19.1M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$15.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.04M |
| 2 |
SCM
Segantii Capital Management
Hong Kong
|
-$2.62M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.53M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.08M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$917K |
PRVB Hedge Fund Activity: Q2 2020 in Review
106 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q2 2020, worth a combined $294M — up 206% from $96.2M a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new PRVB positions and 12 closed out — a net gain of 43 holders — while 30 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $27.8M. The largest seller was Susquehanna International Group, cutting an estimated $3.04M.
- 106 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q2 2020, up from 63 in Q1 2020.
- Funds reported $294M of Provention Bio, Inc. Common Stock stock for Q2 2020, up 206% quarter-over-quarter.
- 55 funds opened new Provention Bio, Inc. Common Stock positions in Q2 2020 and 12 closed out, a net change of +43 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $27.8M added.
- The largest Provention Bio, Inc. Common Stock seller in Q2 2020 was Susquehanna International Group, an estimated $3.04M sold.
Based on aggregated 13F filings for Q2 2020.